Anika Therapeutics
ANIK
156 hedge funds and large institutions have $515M invested in Anika Therapeutics in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 50 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
30% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $1.25M
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
5.71% more ownership
Funds ownership: 75.25% → 80.96% (+5.7%)
6% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 50
4% less capital invested
Capital invested by funds: $539M → $515M (-$24M)
1% less funds holding
Funds holding: 158 → 156 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$85.2M |
| 2 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
+$33.4M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$8.13M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7.15M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$6.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$10.4M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$4.14M |
| 3 |
AAM
AMI Asset Management
Los Angeles,
California
|
-$3.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.57M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.53M |
ANIK Hedge Fund Activity: Q1 2017 in Review
156 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2017, worth a combined $515M — down 4.5% from $539M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ANIK positions and 24 closed out — a net gain of 4 holders — while 53 added to existing stakes and 50 trimmed.
The largest buyer was BlackRock, adding an estimated $85.2M. The largest seller was Thompson Siegel & Walmsley, cutting an estimated $10.4M.
- 156 institutional investors held Anika Therapeutics (ANIK) as of Q1 2017, down from 158 in Q4 2016.
- Funds reported $515M of Anika Therapeutics stock for Q1 2017, down 4.5% quarter-over-quarter.
- 28 funds opened new Anika Therapeutics positions in Q1 2017 and 24 closed out, a net change of +4 holders.
- The largest Anika Therapeutics buyer in Q1 2017 was BlackRock, an estimated $85.2M added.
- The largest Anika Therapeutics seller in Q1 2017 was Thompson Siegel & Walmsley, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2017.